See more : Drone Guarder, Inc. (DRNG) Income Statement Analysis – Financial Results
Complete financial analysis of Alligator Bioscience AB (publ) (ATORX.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alligator Bioscience AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Northern Star Investment Corp. III (NSTC-UN) Income Statement Analysis – Financial Results
- JF Technology Berhad (0146.KL) Income Statement Analysis – Financial Results
- DB Finance No.12 SPAC (477760.KQ) Income Statement Analysis – Financial Results
- Forum Engineering Inc. (7088.T) Income Statement Analysis – Financial Results
- Bluejay Diagnostics, Inc. (BJDX) Income Statement Analysis – Financial Results
Alligator Bioscience AB (publ) (ATORX.ST)
About Alligator Bioscience AB (publ)
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of cancer. The company also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.11M | 35.70M | 12.94M | 4.35M | 4.36M | 26.96M | 56.88M | 58.24M | 289.80M | 1.23M |
| Cost of Revenue | 218.79M | 147.73M | 86.98M | 82.32M | 145.38M | 121.16M | 3.20M | 2.55M | 31.04M | 44.84M |
| Gross Profit | -160.69M | -112.03M | -74.04M | -77.97M | -141.02M | -94.20M | 53.67M | 55.69M | 258.75M | -43.61M |
| Gross Profit Ratio | -276.53% | -313.84% | -572.04% | -1,791.54% | -3,235.82% | -349.43% | 94.37% | 95.62% | 89.29% | -3,533.87% |
| Research & Development | 264.58M | 134.93M | 68.04M | 69.10M | 132.02M | 102.92M | 60.34M | 39.81M | 49.49M | 42.35M |
| General & Administrative | 0.00 | 0.00 | 18.94M | 13.22M | 13.36M | 18.24M | 18.61M | 23.47M | 49.34M | 48.61M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 42.51M | 31.21M | 18.94M | 13.22M | 13.36M | 18.24M | 18.61M | 23.47M | 49.34M | 48.61M |
| Other Expenses | 0.00 | 93.07M | 67.32M | 66.07M | 72.15M | 57.98M | 40.96M | 29.55M | 39.45M | 28.55M |
| Operating Expenses | 307.09M | 228.00M | 154.31M | 148.39M | 217.53M | 179.14M | 119.90M | 92.83M | 88.79M | 77.15M |
| Cost & Expenses | 307.09M | 228.00M | 154.31M | 148.39M | 217.53M | 179.14M | 119.90M | 92.83M | 88.79M | 77.15M |
| Interest Income | 1.88M | 3.00K | 231.00K | 1.46M | 43.00K | 116.00K | 36.00K | 468.00K | 42.00K | 431.00K |
| Interest Expense | 483.00K | 646.00K | 231.00K | 313.00K | 419.00K | 0.00 | 19.00K | 4.00K | 1.00K | 1.00K |
| Depreciation & Amortization | 10.49M | 11.77M | 11.14M | 11.52M | 11.55M | 5.90M | 3.20M | 2.55M | 12.67M | 3.19M |
| EBITDA | -237.61M | -180.99M | -130.36M | -131.46M | -197.73M | -144.14M | -60.55M | -45.80M | 220.05M | -73.96M |
| EBITDA Ratio | -408.92% | -507.05% | -1,007.19% | -3,020.70% | -4,546.70% | -534.63% | -106.44% | -2.67% | 75.93% | -5,963.94% |
| Operating Income | -248.98M | -192.79M | -141.57M | -144.30M | -214.52M | -153.08M | -62.30M | -56.08M | 203.01M | -77.21M |
| Operating Income Ratio | -428.49% | -540.09% | -1,093.76% | -3,315.67% | -4,922.42% | -567.83% | -109.54% | -96.29% | 70.05% | -6,257.13% |
| Total Other Income/Expenses | 397.00K | -614.00K | -171.00K | 1.00M | 4.41M | 3.04M | -1.46M | 7.73M | 4.37M | 431.00K |
| Income Before Tax | -248.59M | -193.40M | -141.74M | -143.30M | -210.11M | -150.04M | -63.76M | -48.36M | 207.38M | -76.78M |
| Income Before Tax Ratio | -427.81% | -541.81% | -1,095.08% | -3,292.65% | -4,821.29% | -556.56% | -112.10% | -83.03% | 71.56% | -6,222.20% |
| Income Tax Expense | 0.00 | -6.00K | 231.00K | 313.00K | 419.00K | 2.14M | -711.00K | 8.35M | 6.37M | 369.00K |
| Net Income | -248.59M | -193.40M | -141.97M | -143.61M | -210.53M | -150.04M | -63.76M | -48.36M | 207.38M | -76.78M |
| Net Income Ratio | -427.81% | -541.79% | -1,096.86% | -3,299.84% | -4,830.91% | -556.56% | -112.10% | -83.03% | 71.56% | -6,222.20% |
| EPS | -0.55 | -0.88 | -0.96 | -1.22 | -1.57 | -1.12 | -0.48 | -0.43 | 1.87 | -0.58 |
| EPS Diluted | -0.55 | -0.88 | -0.96 | -1.22 | -1.57 | -1.12 | -0.48 | -0.43 | 1.58 | -0.58 |
| Weighted Avg Shares Out | 448.49M | 220.58M | 147.96M | 117.79M | 134.06M | 134.06M | 133.86M | 112.88M | 111.17M | 131.47M |
| Weighted Avg Shares Out (Dil) | 448.49M | 220.58M | 147.96M | 117.79M | 134.06M | 134.06M | 133.86M | 112.88M | 131.47M | 131.47M |
Source: https://incomestatements.info
Category: Stock Reports